6CM
AUPH icon

683 Capital Management’s Aurinia Pharmaceuticals AUPH Stock Holding History

683 Capital Management’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-400,000
Closed -$2.28M – 144
2024
Q2 		$2.28M Sell
400,000
-215,000
-35% -$1.13M 0.17% 87
2024
Q1 		$3.08M Buy
615,000
+395,000
+180% +$2.68M 0.23% 71
2023
Q4 		$1.98M Buy
+220,000
New +$1.81M 0.16% 78

Other funds holding AUPH

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

683 Capital Management's AUPH Position: Q3 2024 in Review

683 Capital Management sold out of Aurinia Pharmaceuticals (AUPH) in Q3 2024, closing a stake of 400,000 shares — an estimated $2.28M sold.

683 Capital Management first reported a position in AUPH in Q4 2023 and held it in 3 quarters. The position peaked at $3.08M in Q1 2024. 183 funds tracked by Wall St. Rank hold AUPH as of Q3 2024.

  • 683 Capital Management reported no remaining Aurinia Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • 683 Capital Management sold 400,000 Aurinia Pharmaceuticals shares in Q3 2024, an estimated $2.28M.
  • 683 Capital Management first reported a position in Aurinia Pharmaceuticals in Q4 2023 and held it in 3 quarters.
  • 683 Capital Management's Aurinia Pharmaceuticals position peaked at $3.08M in Q1 2024.
  • 183 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q3 2024.

Based on 683 Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.